4Sc AG

4SC AG is a clinical-stage biopharmaceutical company dedicated to advancing novel small-molecule therapeutics for oncology indications characterized by significant unmet patient needs. Among its lead candidates is Resminostat, an orally administered histone deacetylase inhibitor, currently undergoing Phase II clinical assessment for cutaneous T-cell lymphoma. Additionally, Domatinostat, an oral small molecule, is being evaluated in a Phase Ib/II trial for melanoma and a separate Phase II clinical trial for gastrointestinal tumors. Furthermore, 4SC AG strategically out-licenses its cancer-focused compounds to other pharmaceutical and biotechnology partners. The company also collaborates with the Netherlands Cancer Institute to investigate Domatinostat's efficacy in a neoadjuvant setting for melanoma patients. Founded in 1997, 4SC AG maintains its corporate headquarters in Planegg, Germany.